PT - JOURNAL ARTICLE AU - Ariamanesh, Mona AU - Porouhan, Pejman AU - PeyroShabany, Babak AU - Fazilat-Panah, Danial AU - Dehghani, Mansoureh AU - Nabavifard, Maryam AU - Hatami, Farbod AU - Fereidouni, Mohammad AU - Welsh, James S. AU - Javadinia, Seyed Alireza TI - Immunogenicity and Safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy AID - 10.1101/2021.09.02.21262760 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.02.21262760 4099 - http://medrxiv.org/content/early/2021/09/06/2021.09.02.21262760.short 4100 - http://medrxiv.org/content/early/2021/09/06/2021.09.02.21262760.full AB - Objective Patients with malignancy suffer from a compromised immune system due to either the effects of malignancies or treatments. Cancer patients are at higher risk of different infections particularly SARS-CoV2 and usually produce weaker response to vaccines. The aim of this study was to evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine (Sinopharm, BBIBP-CorV) in patients with malignancy.Material and Method In total 364 patients with cancer (median age: 54 years old, F/M ratio: 217/147) who received two doses of Sinopharm vaccine were enrolled in this study. Vaccine related side effects was assessed by a questionnaire and the presence of SARS-CoV-2 anti-Spike protein (S) IgG and neutralizing antibody two months following vaccination were measured by immunological methods.Results Injection site pain and fever were the most common local and systemic side effects in vaccine receivers. Two months after the first dose, anti-S IgG and neutralizing antibody were detectable in 77.1% and 80.7% of all participants, respectively with an overall response to either or both measured in 86.9% of patients The rate of seroconversion was lower in older age, those with hematological malignancies and chemotherapy receivers.Conclusion The result of study confirmed the safety and short-term efficacy of Sinopharm inactivated vaccine (BBIBP-CorV) in patients with different type of malignancies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Sabzevar University of Medical Sciences (grant number 400004) and Neyshabur University of Medical Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol of the study was approved by the Ethics Committee of Sabzevar University of Medical Sciences (IR.MEDSAB.REC.1400.027) and a written informed consent form was obtained from the patients or the legal guardian.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analyzed during this study can be accessed through direct communication with the corresponding author and the agreement of all research team members.